DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Wet Age-Related Macular Degeneration (Current and Future Uptake of Anti-VEGF Agents for Wet AMD) | Physician & Payer Forum | China | 2015
How Does Cost versus Dosing Impact Prescriber Preferences and Payer Policy? The prevalence of age-related macular degeneration (AMD) is increasing with the aging population in China. Therapies…
Wet Age-Related Macular Degeneration (Current and Future Uptake of Anti-VEGF Agents for Wet AMD) | Physician & Payer Forum | Brazil/Mexico | 2015
How Does Cost Versus Dosing Impact Prescriber Preferences and Payer Policy? Agents that target vascular endothelial growth factor (VEGF) have expanded the treatment armamentarium in Brazil and…
Wet AMD (The Anti-VEGF Era and Beyond in Wet AMD: The Impact of Clinical Attributes and Market Access Status on Current and Future Prescribing Decisions Among Retinal Specialists) | Physician & Payer Forum | EU5 | 2014
Treatment for the wet (exudative, neovascular) form of age-related macular degeneration (AMD) in Europe is characterized by several current therapies targeting vascular endothelial growth factor (…
Anti-VEGF Agents: How Does Cost Versus Dosing Impact the Wet AMD Treatment Algorithm Among Retinal Specialists in the United States? | Physician & Payer Forum | US | 2014
While Genentech’s Lucentis continues to be the gold-standard treatment for wet age-related macular degeneration (AMD) in the United States, off-label use of Genentech’s Avastin (often…
Wet Age-Related Macular Degeneration | Treatment Algorithms | Claims Data Analysis | US | 2014
Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness. More than half of advanced AMD patients suffer the wet (exudative, neovascular) form of the disease,…
